Principal Financial Group Inc. Sells 184,961 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

Principal Financial Group Inc. reduced its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 24.3% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 577,727 shares of the biopharmaceutical company’s stock after selling 184,961 shares during the quarter. Principal Financial Group Inc. owned 0.44% of Dynavax Technologies worth $6,436,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of DVAX. GAMMA Investing LLC lifted its position in shares of Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 1,685 shares in the last quarter. US Bancorp DE increased its holdings in shares of Dynavax Technologies by 291.4% in the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,034 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Dynavax Technologies by 44.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 1,679 shares during the period. Algert Global LLC bought a new stake in shares of Dynavax Technologies during the second quarter worth $140,000. Finally, Sanctuary Advisors LLC acquired a new position in shares of Dynavax Technologies during the second quarter valued at $182,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $29.00 price objective on shares of Dynavax Technologies in a research report on Friday, November 8th. The Goldman Sachs Group dropped their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th.

Dynavax Technologies Stock Performance

Shares of NASDAQ:DVAX opened at $12.17 on Thursday. The firm’s 50 day simple moving average is $11.42 and its 200 day simple moving average is $11.31. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $15.01. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of 93.62 and a beta of 1.34. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.